BioBreakthroughs

Join us on the latest episode! Our Guest: Nolan Townsend, CEO of LEXEO Therapeutics

What you'll get out of this episode:

• Can you tell us about your background and what led you to LEXEO?
• What product candidates are development at LEXEO?
• How is what LEXEO is developing different than the current treatments in the neurological and cardiac spaces?
• At BIO you spoke to the topic of accelerated approval, can you provide some perspective on the pathways needed for accelerated approval in gene therapy?
• How does gene therapy address patient needs across disease areas?
• What's next?

Full Video and more info click here: Slice Of Healthcare Website

Our sponsors for this episode are:
Sage Growth Partners https://sage-growth.com/
FlipMD by GoodRX https://www.goodrx.com/
Quantum Health https://quantum-health.com/

To learn more about LEXEO Therapeutics please use the links below:
- LEXEO TX LinkedIN - LEXEO TX Website -

Join us on the latest episode! Our Guest: Sandra von Meier, Head of Business Development at Debiopharm

What you'll get out of this episode:

- Sandra's background

- Overview of Debiopharm

- Tell us about Debiopharm’s approach to drug development. How does it work with startups to enhance innovation and expedite clinical trial timelines?

- What steps can companies take to improve patient quality of life in drug development?

- As the world continues to face a global drug shortage, how does Debiopharm bridge the gap between disruptive research and real-world application to ensure patients receive the life-saving drugs they need?

- What’s next for the future of biopharma?

To learn more about Debiopharm: https://www.debiopharm.com/

Full Episode and more info here: https://loom.ly/dkKu8RA

Our sponsors for this episode are: 
Sage Growth Partners https://www.sage-growth.com
FlipMD by GoodRX https://www.goodrx.com/
Quantum Health https://quantum-health.com/

This exciting episode is a conversation with David Esposito, President and CEO of ONL Therapeutics!

We had the pleasure of hosting David Esposito, a visionary leader in the field of biotechnology as the President and CEO of ONL Therapeutics. Join us as we dive deep into the fascinating world of retinal diseases and explore the future of biotech!

In this episode, we covered:

- David's inspiring background and journey to becoming a leader in the industry

- An insightful overview of ONL Therapeutics and their groundbreaking work in the field of retinal diseases.

- The evolving landscape of retinal disease treatment and the remarkable progress made over the years.

- The role of artificial intelligence and machine learning in shaping the future of biotechnology.

- What's next for ONL Therapeutics?

We'd like to thank our sponsors for this episode, Sage Growth Partners, a leading healthcare consultancy, their support enables us to bring you thought-provoking discussions with industry experts. For more information, please go to www.sage-growth.com. 

Learn more about ONL Therapeutics follow these links: 

LinkedIn - Website

Also, be sure to follow Slice of Healthcare on our social channels:

Website  - LinkedIn - Twitter - YouTube - Newsletter

Don't miss out! Subscribe to our YouTube channel to catch all the engaging episodes and stay up-to-date with the latest advancements in biotech: https://www.youtube.com/@UCPuxsHtzFktm1XezuJp-KoA

Our Guest: Richard Brandon, Chief Scientific Officer at Immunexpress

What you'll get out of this episode:

• Richard's background
• Overview of Immunexpress
• The impact of a lack of reliable sepsis diagnostics
• SeptiCyte technology
• What's next?

Our sponsors for this episode are Sage Growth Partners

Sage Growth Partners accelerates commercial success for healthcare organizations through a singular focus on growth. The company helps its clients thrive amid the complexities of a rapidly changing marketplace with deep domain expertise and an integrated application of research, strategy, and marketing. For more information, please go to www.sage-growth.com & follow Sage Growth Partners on social media - @sagegrowthpartners

Learn more about Immunexpress follow these links: 

LinkedIn - Website 

Also, be sure to follow Slice of Healthcare on our social channels:

Website  - LinkedIn - Twitter - YouTube - Newsletter

Our Guest: Rohit Nambisan, CEO & Co-Founder at Lokavant

What you'll get out of this episode:

• Rohit's background
• Overview of Lokavant
• The biggest data challenges in clinical trials today
• It's mentioned that late-phase trials are now generating 3x more data than 10 years ago. How is Lokavant managing this influx of data?
• The limitations of legacy systems and processes in handling the data from clinical trials
• How Lokavant's approach differs
• What's next?

Our sponsors for this episode are Sage Growth Partners

Sage Growth Partners accelerates commercial success for healthcare organizations through a singular focus on growth. The company helps its clients thrive amid the complexities of a rapidly changing marketplace with deep domain expertise and an integrated application of research, strategy, and marketing. For more information, please go to www.sage-growth.com & follow Sage Growth Partners on social media - @sagegrowthpartners

Our Guest: Joel Morse, CEO at Curavit Clinical Research

What you'll get out of this episode:

• Joel's background
• Curavit Overview
• CRO and virtual clinical site services for clinical trials
• Traditional vs. Decentralized Clinical Trials
• What the future of this space looks like?

Our sponsors for this episode are Sage Growth Partners

Sage Growth Partners accelerates commercial success for healthcare organizations through a singular focus on growth. The company helps its clients thrive amid the complexities of a rapidly changing marketplace with deep domain expertise and an integrated application of research, strategy, and marketing. For more information, please go to www.sage-growth.com & follow Sage Growth Partners on social media - @sagegrowthpartners

Our Guest: Chris Bahl, Co-Founder, President & Chief Scientific Officer at AI Proteins

What you'll get out of this episode:

• Bahl's background
• Overview of AI Proteins
• How they are utilizing computational protein design to engineer synthetic miniproteins therapeutics that can bind to any target
• The process and challenges
• Key differentiators
• Their impact on the future of medicine

Our sponsors for this episode are Sage Growth Partners

Sage Growth Partners accelerates commercial success for healthcare organizations through a singular focus on growth. The company helps its clients thrive amid the complexities of a rapidly changing marketplace with deep domain expertise and an integrated application of research, strategy, and marketing. For more information, please go to www.sage-growth.com & follow Sage Growth Partners on social media - @sagegrowthpartners

Our Guest: #2 - Spiro Rombotis, CEO at Cyclacel Pharmaceuticals

What you'll get out of this episode:

• Rombotis's background and an overview of Cyclacel
• Which part of the cell cycle they're targeting?
• What their leading candidates are, and the current clinical trial statuses of each.
• What makes their CDK inhibitor strategy unique compared to other biopharmaceutical companies?
• Their PLK1 program
• Near-term milestones and what's next?

Our sponsors for this episode are Sage Growth Partners

Sage Growth Partners accelerates commercial success for healthcare organizations through a singular focus on growth. The company helps its clients thrive amid the complexities of a rapidly changing marketplace with deep domain expertise and an integrated application of research, strategy, and marketing. For more information, please go to www.sage-growth.com & follow Sage Growth Partners on social media - @sagegrowthpartners

Our Guest: Kendalle Burlin O’Connell, Esq., President & CEO at MassBio

What you'll get out of this episode:

• Kendalle's career journey
• Workforce training program
• ResearcHERS
• Trends to watch

Our sponsors for this episode are Sage Growth Partners

Sage Growth Partners accelerates commercial success for healthcare organizations through a singular focus on growth. The company helps its clients thrive amid the complexities of a rapidly changing marketplace with deep domain expertise and an integrated application of research, strategy, and marketing. For more information, please go to www.sage-growth.com & follow Sage Growth Partners on social media - @sagegrowthpartners